The ongoing debate over drug prices remains “too narrow, focusing on the list price of a handful of innovative medicines,” National Pharmaceutical Council (NPC) President and CEO Dan Leonard writes in a recent column on Specialty Pharmacy Times.
Leonard writes that recent research by NPC and RTI Health Solutions found that biopharmaceuticals carry a “modest” price tag for “substantial” benefits, and that a drug’s price involves “more than just what is maid for a medication.”
“The American health care system is incredibly complex, made up of countless interrelated entities that research, regulate, deliver, evaluate, and supply the industry as we know it today,” Leonard writes. “As we debate who should pay for health care and how, it is critical to make clear that we expect to get for those payments: high-quality, cost-effective care that improves patient outcomes — in other words: value.”
To read Leonard’s full column on Specialty Pharmacy Times, click here.